We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.31 | -0.63% | 49.02 | 48.95 | 48.98 | 2,503 | 12:16:52 |
From May 2019 to May 2024
By Noemie Bisserbe
PARIS--French drugmaker Sanofi SA (SAN.FR) said Thursday it had received approval from the U.S. Food and Drug Administration for Adlyxin, a medicine indicated to treat adults with type 2 diabetes.
Adlyxin has already been approved under the proprietary name, Lyxumia in more than 60 countries and marketed in over 40, including most EU countries, Japan, Brazil, Mexico and India.
-Write to Noemie Bisserbe at noemie.bisserbe@wsj.com
(END) Dow Jones Newswires
July 28, 2016 01:27 ET (05:27 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
